HUP0104709A3 - Use of erythropoietin or erythropoietin derivatives for the manufacture of a medicament for treatment of cerebral ischaemia - Google Patents

Use of erythropoietin or erythropoietin derivatives for the manufacture of a medicament for treatment of cerebral ischaemia

Info

Publication number
HUP0104709A3
HUP0104709A3 HU0104709A HUP0104709A HUP0104709A3 HU P0104709 A3 HUP0104709 A3 HU P0104709A3 HU 0104709 A HU0104709 A HU 0104709A HU P0104709 A HUP0104709 A HU P0104709A HU P0104709 A3 HUP0104709 A3 HU P0104709A3
Authority
HU
Hungary
Prior art keywords
erythropoietin
medicament
manufacture
treatment
derivatives
Prior art date
Application number
HU0104709A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Gleiter Christoph
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7891015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0104709(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gleiter Christoph filed Critical Gleiter Christoph
Publication of HUP0104709A2 publication Critical patent/HUP0104709A2/hu
Publication of HUP0104709A3 publication Critical patent/HUP0104709A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
HU0104709A 1998-12-14 1999-12-13 Use of erythropoietin or erythropoietin derivatives for the manufacture of a medicament for treatment of cerebral ischaemia HUP0104709A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19857609A DE19857609A1 (de) 1998-12-14 1998-12-14 Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
PCT/EP1999/009864 WO2000035475A2 (de) 1998-12-14 1999-12-13 Verfahren zur behandlung von cerebralen ischämien sowie verwendung von erythropoietin oder erythropoietin-derivaten zur behandlung von cerebralen ischämien

Publications (2)

Publication Number Publication Date
HUP0104709A2 HUP0104709A2 (hu) 2002-04-29
HUP0104709A3 true HUP0104709A3 (en) 2002-05-28

Family

ID=7891015

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0104709A HUP0104709A3 (en) 1998-12-14 1999-12-13 Use of erythropoietin or erythropoietin derivatives for the manufacture of a medicament for treatment of cerebral ischaemia

Country Status (26)

Country Link
US (1) US7514072B1 (enExample)
EP (1) EP1140139B2 (enExample)
JP (2) JP4750947B2 (enExample)
KR (1) KR100774827B1 (enExample)
CN (1) CN1187085C (enExample)
AT (1) ATE253932T1 (enExample)
AU (1) AU766216C (enExample)
BG (1) BG65417B1 (enExample)
BR (1) BR9916197A (enExample)
CA (1) CA2353553C (enExample)
DE (2) DE19857609A1 (enExample)
DK (1) DK1140139T4 (enExample)
ES (1) ES2211218T5 (enExample)
HK (1) HK1042655B (enExample)
HU (1) HUP0104709A3 (enExample)
ID (1) ID29107A (enExample)
IL (2) IL143579A0 (enExample)
MX (1) MXPA01005971A (enExample)
NO (1) NO330079B1 (enExample)
NZ (1) NZ541591A (enExample)
PL (1) PL202483B1 (enExample)
PT (1) PT1140139E (enExample)
RO (1) RO121409B1 (enExample)
RU (1) RU2242991C2 (enExample)
WO (1) WO2000035475A2 (enExample)
ZA (1) ZA200104626B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7309687B1 (en) 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
KR101012932B1 (ko) * 1999-04-13 2011-02-08 더 케네쓰 에스. 워렌 인스티튜트 인코포레이티드 말초 투여된 에리트로포에틴에 의한 흥분조직의 기능조절법
US7078376B1 (en) 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
DE10043457A1 (de) * 2000-09-04 2002-03-28 Hannelore Ehrenreich Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
PA8536201A1 (es) * 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
WO2003018782A2 (en) 2001-08-30 2003-03-06 Stem Cell Therapeutics Inc. Differentiation of neural stem cells and therapeutic use theeof
ATE541921T1 (de) 2001-09-14 2012-02-15 Stem Cell Therapeutics Inc Prolaktin-induzierte zunahme an neuronalen stammzellen und dessen therapeutische anwendung
DE10219545A1 (de) * 2002-04-26 2003-11-06 Lang Florian Regulation der Apoptose
EP1535065A4 (en) * 2002-06-11 2007-07-11 Burnham Inst NEUROPROTECTOR SYNERGY OF ERYTHROPOIETIN AND INSULIN-LIKE GROWTH FACTOR
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
MXPA05010345A (es) * 2003-03-27 2006-03-08 Johnson & Johnson Uso de la eritropoyetina en la recuperacion del accidente cerebrovascular.
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
US20070111932A1 (en) * 2003-07-31 2007-05-17 Stem Cell Therapeutics Inc. Method of enhancing and/or inducing neuronal migration using erythropoietin
ZA200603396B (en) 2003-09-29 2007-11-28 Warren Pharmaceuticals Inc Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
AU2004285448C1 (en) 2003-10-23 2021-08-19 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile injectable aripiprazole formulation and method
WO2005077404A1 (en) 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Use of luteinizing hormone (lh) and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
US9988427B2 (en) 2005-05-13 2018-06-05 Charite Universitaetsmedizen-Berlin Erythropoietin variants
EP1736481A1 (en) 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
EP1933814A2 (en) * 2005-09-15 2008-06-25 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
EP1928488A4 (en) 2005-09-27 2009-07-22 Stem Cell Therapeutics Corp REGULATION OF OLIGODENDROCYTE PRECURSOR CELL PROLIFERATION WITH PROLACTIN
CA2643502A1 (en) * 2006-03-17 2007-09-27 Stem Cell Therapeutics Corp. Dosing regimes for lh or hcg and epo for treatment of neurological disorders
NZ573792A (en) * 2006-06-07 2011-09-30 Univ Tokushima Treatment of ischemic disease using erythropoietin mobilised mononuclear cells
JP4879349B2 (ja) * 2007-07-31 2012-02-22 大塚製薬株式会社 アリピプラゾール懸濁液及び凍結乾燥製剤の製造方法
RU2446834C2 (ru) * 2010-06-15 2012-04-10 Елена Александровна Лебедева Способ лечения пострадавших с сочетанной черепно-мозговой травмой
US9956265B2 (en) 2011-04-26 2018-05-01 Ajou University Industry-Academic Cooperation Foundation Composition for aiding surgical procedures for treating ischemic vascular diseases
RU2495688C1 (ru) * 2012-03-28 2013-10-20 Государственное бюджетное учреждение здравоохранения Центр организации специализированной медицинской помощи "Челябинский государственный институт лазерной хирургии" Способ лечения ишемии головного мозга в эксперименте
US9610444B2 (en) 2013-03-15 2017-04-04 Pacesetter, Inc. Erythropoeitin production by electrical stimulation
KR20190052855A (ko) 2017-11-09 2019-05-17 대한제당 주식회사 페길레이션된 에리스로포이에틴을 포함하는 허혈성 뇌질환 치료용 조성물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
JPS6197229A (ja) 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US5013718A (en) * 1986-11-21 1991-05-07 Amgen, Inc. Method for treating iron overload using EPO
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
EP0452484B2 (en) 1989-11-06 2004-07-28 Cell Genesys, Inc. Production of proteins using homologous recombination
ATE156189T1 (de) 1989-12-22 1997-08-15 Applied Research Systems Modifikation der endogenen genexpression mit hilfe eines regulatorischen elements mittels homologe rekombination
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
JP3537151B2 (ja) 1991-12-26 2004-06-14 中外製薬株式会社 脳機能障害による疾患の予防・治療薬
RU2068268C1 (ru) * 1992-03-19 1996-10-27 Учебно-научный центр Медицинского центра при Правительстве РФ Способ профилактики церебро-васкулярных заболеваний
US5614184A (en) 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US5661125A (en) 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
EP0744953A4 (en) 1993-04-29 1998-05-06 Abbott Lab METHODS AND COMPOSITIONS OF ERYTHROPO ETINE ANALOGS
ZA946122B (en) 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
SE520730C2 (sv) 1995-01-20 2003-08-19 Eskil Elmer Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US6165783A (en) 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
KR101012932B1 (ko) 1999-04-13 2011-02-08 더 케네쓰 에스. 워렌 인스티튜트 인코포레이티드 말초 투여된 에리트로포에틴에 의한 흥분조직의 기능조절법
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs

Also Published As

Publication number Publication date
DK1140139T3 (da) 2004-03-15
HK1042655B (zh) 2005-09-23
MXPA01005971A (es) 2002-03-27
ZA200104626B (en) 2002-09-06
CN1335776A (zh) 2002-02-13
JP2011079860A (ja) 2011-04-21
WO2000035475A2 (de) 2000-06-22
RU2242991C2 (ru) 2004-12-27
AU766216C (en) 2004-11-11
BG105575A (en) 2002-01-31
WO2000035475A3 (de) 2000-10-19
DK1140139T4 (da) 2009-06-08
NO330079B1 (no) 2011-02-14
DE19857609A1 (de) 2000-06-15
EP1140139B1 (de) 2003-11-12
EP1140139A2 (de) 2001-10-10
PL349335A1 (en) 2002-07-15
CN1187085C (zh) 2005-02-02
AU766216B2 (en) 2003-10-09
KR100774827B1 (ko) 2007-11-07
HUP0104709A2 (hu) 2002-04-29
ATE253932T1 (de) 2003-11-15
BG65417B1 (bg) 2008-07-31
DE59907752D1 (de) 2003-12-18
EP1140139B2 (de) 2009-03-18
NZ541591A (en) 2007-08-31
NO20012896D0 (no) 2001-06-12
PT1140139E (pt) 2004-04-30
RO121409B1 (ro) 2007-05-30
JP4750947B2 (ja) 2011-08-17
ES2211218T5 (es) 2009-06-03
US7514072B1 (en) 2009-04-07
EP1140139B9 (de) 2004-03-31
HK1042655A1 (en) 2002-08-23
PL202483B1 (pl) 2009-06-30
BR9916197A (pt) 2001-09-04
KR20010082346A (ko) 2001-08-29
IL143579A (en) 2007-10-31
NO20012896L (no) 2001-08-14
JP2002532432A (ja) 2002-10-02
IL143579A0 (en) 2002-04-21
ES2211218T3 (es) 2004-07-01
CA2353553A1 (en) 2000-06-22
AU2283100A (en) 2000-07-03
CA2353553C (en) 2011-05-17
ID29107A (id) 2001-07-26

Similar Documents

Publication Publication Date Title
HUP0104709A3 (en) Use of erythropoietin or erythropoietin derivatives for the manufacture of a medicament for treatment of cerebral ischaemia
PL350984A1 (en) 1,4−benzothiazepine−1,1−dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof
IL196301A0 (en) Medicament for the treatment of hapatitis c
IL150742A0 (en) Pyridopyrimidinone derivatives for the treatment of neurodegenerative disease
IL148230A0 (en) Methods for determining the physiological state of a plant
IL146162A0 (en) Macrolide compounds for the treatment of dry eye
GB2367010B (en) Body treatment product
AU4498201A (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment ofpain
AU3814599A (en) Use of erythropoietin for the treatment of haemochromatoses
EP1181308A4 (en) METHODS OF TREATING NEURONAL DEMENTIA ASSOCIATED WITH ATROPHY
PT1698338E (pt) S-metil-di-hidro-ziprasidona para o tratamento de distúrbios psiquiátricos
AU3071899A (en) Use of pkc-inhibitors for the manufacture of a medicament for the treatment of asthma
EP1240156A4 (en) 3-METHYL CHROME OR THIOCHROME DERIVATIVES
IL123422A (en) USE OF 7alpha-METHYL-17alpha-ETHYNYL-ESTRANE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE PROPHYLAXIS OR THE TREATMENT OF ATHEROSCLEROSIS
IL127826A0 (en) Restenosis drug therapy
GB9904935D0 (en) Medicaments
SI1068184T1 (en) N-aryloxyethylamine derivatives for the treatment of depression
GB9910545D0 (en) The treatment of acarids
GB9911614D0 (en) Body treatment product
SI1061940T1 (en) Use of follistatin for the manufacture of a medicament for the treatment of muscle-related disorders
CA86256S (en) Disposable diaper or the like
CA86255S (en) Disposable diaper or the like
CA86254S (en) Disposable diaper or the like
GB9919126D0 (en) Glaucoma treatment
GB9925550D0 (en) Glaucoma treatment

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished